HYPERRAB SOLUTION

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

RABIES IMMUNOGLOBULIN (HUMAN)

Disponible desde:

GRIFOLS THERAPEUTICS LLC

Código ATC:

J06BB05

Designación común internacional (DCI):

RABIES IMMUNOGLOBULIN

Dosis:

300UNIT

formulario farmacéutico:

SOLUTION

Composición:

RABIES IMMUNOGLOBULIN (HUMAN) 300UNIT

Vía de administración:

INTRAMUSCULAR

Unidades en paquete:

15G/50G

tipo de receta:

Schedule D

Área terapéutica:

SERUMS

Resumen del producto:

Active ingredient group (AIG) number: 0110666003; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2019-03-13

Ficha técnica

_ _
_ _
_HYPERRAB® (Rabies Immunoglobulin [Human]) _
_Page 1 of 17_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
HYPERRAB®
Rabies Immunoglobulin [Human]
Injectable Solution, 300 IU per mL
For infiltration and intramuscular injection
Manufacturer’s Standard
Passive Immunizing Agent
ATC: J06BB05
Manufactured by:
Grifols Therapeutics LLC
8368 U.S. 70 Bus. Hwy West
Clayton, North Carolina
27520
U.S.A.
Imported and Distributed by:
Grifols Canada Ltd.
5060 Spectrum Way, Suite 405
Mississauga, Ontario
L4W 5N5
Date of Initial
Authorization:
July 3, 1975
Date of Revision:
[TBD]
Submission Control Number: 247808 Date of Approval: March 19, 2021
_ _
_ _
_ _
_HYPERRAB® (Rabies Immunoglobulin [Human]) _
_Page 2 of 17_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
................................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics.............................................................................................................4
2
CONTRAINDICATIONS
...................................................................................................4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
..............................................................4
4
DOSAGE AND
ADMINISTRATION...................................................................................5
4.2
Recommended Dose and Dosage
Adjustment.......................................................5
4.4
Administration.....................................................................................................5
5
OVERDOSAGE
...........